|
Sign In to gain access to subscriptions and/or personal tools.
|
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Cindy A. Farman
Sierra Biomedical, a Division of Charles River Sparks, Nevada, cafarman{at}ucdavis.edu
Doug J. Kornbrust
Sierra Biomedical, a Division of Charles River Sparks, Nevada
Antisense oligodeoxynucleotide compounds (AS ODN) are being developed as therapeutics for various disease indications. Their safety and pharmacokinetics are most commonly evaluated in rodents and nonhuman primates. Traditional AS ODN are short, single strands of DNA, and they target specific mRNA sequences. Plasma clearance of AS ODN is rapid, broad tissue distribution occurs, and elimination is by nuclease metabolism. Structural modifications to AS ODN have been made to enhance their efficacy and improve their safety. A number of class effects are observed with AS ODN that are unrelated to the specific targeted mRNA sequence. Acute effects include activation of the alternative complement pathway and inhibition of the intrinsic coagulation pathway. In monkeys, rodents, and dogs given repeated doses of AS ODN, accumulation of AS ODN and/or metabolites occurs in the form of basophilic granules in various tissues, including the kidney, lymph nodes and liver. A new potential therapeutic application of ODN is that of immune stimulation. Immunostimulatory ODN (IS ODN) are being investigated for use in treating cancer, infectious disease, and allergy. For the development of both AS and IS ODN, primates will continue to be important for safety assessment.
Key Words: Antisense • monkey • oligodeoxynucleotide • immune stimulatory • primate • CpG motif.
References
- Ballas ZK, Krieg AM, Warren T., Rasmussen W., Davis HL, Waldschmidt M., Weiner GJ (2001). Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167: 4878— 4886.[Abstract/Free Full Text]
- Dalpke AH, Zimmerman S., Albrecht I., Heeg K. ( 2002). Phosphodiester CpG oligonucleotides as adjuvants: Polyguanosine runs enhance cellular uptake and improve immunostimulatory activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106: 102—112.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Henry SP, Geary RS, Yu R., Levin AA (2001). Drug properties of second-generation antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Investig Drugs 2: 1444—1449.[Medline]
[Order article via Infotrieve]
- Henry SP, Giclas PC, Leeds J., Pangburn M., Auletta C., Levin AA, Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Ther 281: 810—816.[Abstract/Free Full Text]
- Henry SP, Taylor J., Midgley L., Levin AA, Kornbrust DJ (1997). Evaluation ofthe toxicity ofISIS 2302, aphosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev 7: 473—481.[Web of Science][Medline]
[Order article via Infotrieve]
- Krieg AM (1999). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489: 107—116.[Medline]
[Order article via Infotrieve]
- Krieg AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709—760.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Monteith DK, Horner MJ, Gillett NA, Butler M., Geary R., Burckin T., Ushiro-Watanabe T., Levin AA (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27: 307—317.[Abstract/Free Full Text]
- Monteith DK, Levin AA (1999). Synthetic oligonucleotides: The development of antisense therapeutics. Toxicol Pathol 27: 8—13.[Abstract/Free Full Text]
- Monteith DK, Henry SP, Howard RB, Flournoy S., Levin AA, Bennett CF, Crooke ST (1997). Immune stimulation—A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12: 421—432.[Medline]
[Order article via Infotrieve]
- Mui B., Sameersingh GR, Semple SC, Hope MJ ( 2001). Immune stimulation by a CpG- containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 298: 1185—1192.[Abstract/Free Full Text]
- Sheehan JP, Lan H-C. (1998). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92: 1617—1625.[Abstract/Free Full Text]
- Tamm I., Dörken B., Hartmann G. (2001). Antisense therapy in oncology: New hope for an old idea? Lancet 358: 489—497.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 31, No. 1 suppl,
119-122 (2003)
DOI: 10.1080/01926230390174995
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. W. Stief
Coagulation Activation by Lipopolysaccharides
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2009;
15(2):
209 - 219.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J.-H. Wang, B. M. Hendry, and C. C. Sharpe
Silencing genes in the kidney: antisense or RNA interference?
Nephrol. Dial. Transplant.,
July 1, 2008;
23(7):
2115 - 2118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Johansen, T. Storni, L. Rettig, Z. Qiu, A. Der-Sarkissian, K. A. Smith, V. Manolova, K. S. Lang, G. Senti, B. Mullhaupt, et al.
Antigen kinetics determines immune reactivity
PNAS,
April 1, 2008;
105(13):
5189 - 5194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Goebl, B. Berridge, V. J. Wroblewski, and P. L. Brown-Augsburger
Development of a Sensitive and Specific in Situ Hybridization Technique for the Cellular Localization of Antisense Oligodeoxynucleotide Drugs in Tissue Sections
Toxicol Pathol,
June 1, 2007;
35(4):
541 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Stief
Thrombin Generation by Exposure of Blood to Endotoxin: A Simple Model to Study Disseminated Intravascular Coagulation
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2006;
12(2):
137 - 161.
[Abstract]
[PDF]
|
|
|
|
|
